Table 2.
Target
|
Major site of secretion (anatomical location)
|
VSG
|
RYGB
|
Ghrelin | X/A-like cells (stomach) | Decrease | Decrease or no change |
GLP1 | L cells (distal gut) | Increase | Increase |
PYY | L cells (distal gut) | Increase | Increase |
Bile acids | Hepatocytes | Increase | Increase |
FGF-15/19 | Ileum | Increase | Increase |
Microbiota | Gut | Change | Change |
Enteroplasticity | Gut | Change | Change |
Multiple factors appear to drive the remission of type 2 diabetes after bariatric surgery, including decreased ghrelin, increased glucagon-like peptide, increased peptide-YY, increased bile acids, increased fibroblast growth factor-15/19, and alteration of microbiota and enteroplasticity. Data are derived from both human and animal studies. GLP1: Glucagon-like peptide 1; FGF: Fibroblast growth factor; PYY: Peptide-YY; RYGB: Roux-en-Y gastric bypass; VSG: Vertical sleeve gastrectomy.